Back to Search Start Over

Non-endometrioid endometrial cancer: analysis of recurrence pattern and identification of prognostic and treatment factors affecting recurrence and survival.

Authors :
Lee SJ
Kang HJ
Kwak YK
Kim M
Kim J
Source :
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] [Strahlenther Onkol] 2023 Sep; Vol. 199 (9), pp. 828-837. Date of Electronic Publication: 2023 Mar 17.
Publication Year :
2023

Abstract

Purpose: We investigated the characteristics of recurrence pattern and survival of patients with non-endometrioid endometrial cancer (NEEC) and attempted to identify prognostic and treatment factors affecting disease-free survival (DFS) and overall survival (OS) of these patients.<br />Methods: Fifty-seven patients with histologically confirmed International Federation of Gynecology and Obstetrics (FIGO) stage IA-IVA NEEC from February 2003 to December 2021 were retrospectively analyzed.<br />Results: The 5‑year DFS and OS rates of the total cohort were 50.6% and 56.1%, respectively. Recurrence occurred in 28 patients (49.1%) during follow-up, and the most common recurrence pattern was distant metastasis (DM; 78.6% of total recurrences). The occurrence of relapse significantly reduced 5‑year OS (recurrence group vs. non-recurrence group: 12.5% vs. 100%; p < 0.001). In univariate analysis, adjuvant radiotherapy (RT) group showed significantly higher 5‑year DFS (56.7% vs. 37.9%; p = 0.04), local recurrence-free survival (91.6% vs. 50.5%; p = 0.01), and regional recurrence-free survival (88.2% vs. 56.5%; p < 0.01) than the non-RT group. In multivariate analysis, advanced FIGO stage was identified as a negative prognostic factor for DFS and OS. Lymphovascular space invasion (LVSI) and adjuvant RT were independent prognostic factors for DFS.<br />Conclusion: The most common recurrence pattern observed in patients with NEEC was DM. FIGO stage and LVSI were identified as prognostic factors for survival, and RT was identified as a therapeutic modality that could increase DFS. To improve the OS of patients with NEEC, the addition of effective chemotherapy that can reduce DM may be important.<br /> (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)

Details

Language :
English
ISSN :
1439-099X
Volume :
199
Issue :
9
Database :
MEDLINE
Journal :
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Publication Type :
Academic Journal
Accession number :
36930247
Full Text :
https://doi.org/10.1007/s00066-023-02061-1